Biotechnology News and Research

RSS

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis.

19 Jul 2013

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec, a leading supplier of R&D services to the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has purchased the Provantis Portal Remote Study Monitoring solution.

19 Jul 2013

HemoShear announces milestone in development of predictive drug safety systems

HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Audentes Therapeutics closes $30 million Series A financing

Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.

18 Jul 2013

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Scientists at the University of Massachusetts Medical School are the first to establish that a naturally occurring X chromosome "off switch" can be rerouted to neutralize the extra chromosome responsible for trisomy 21, also known as Down syndrome, a genetic disorder characterized by cognitive impairment.

18 Jul 2013

Chemical compound from ocean microbe offers potential treatments for anthrax

A team led by William Fenical at Scripps Institution of Oceanography at UC San Diego has discovered a new chemical compound from an ocean microbe in a preliminary research finding that could one day set the stage for new treatments for anthrax and other ailments such as methicillin-resistant Staphylococcus aureus (MRSA).

18 Jul 2013

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

Heart tissue sustains irreparable damage in the wake of a heart attack. Because cells in the heart cannot multiply and the cardiac muscle contains few stem cells, the tissue is unable to repair itself - it becomes fibrotic and cannot contract properly.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Zecotek partners with Hamamatsu to commercialize existing imaging technologies

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its wholly owned subsidiary Zecotek Imaging Systems Pte. Ltd. has signed a joint collaboration partnership agreement with Hamamatsu Photonics (Tokyo: 6965) of Japan to commercialize existing imaging technologies and to collaborate on the upgrade and manufacture of photo detectors, integrated detector modules (IDM) and associated electronics and data acquisition modules for the imaging markets at large.

16 Jul 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

From QIAGEN Manchester Limited 15 Jul 2013

Scientists uncover mechanism that controls cell death processes

Scientists have uncovered the mechanism that controls whether cells that are able to suppress immune responses live or die.

15 Jul 2013

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Ipsen announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School.

15 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

Genome sequencing promises to identify rare mutations that give rise to autism

An international consortium, consisting of Autism Speaks, Duke University School of Medicine, The Hospital for Sick Children of Toronto, BGI and other institutes, has investigated the genetic variants in 32 families with Autism Spectrum Disorder (ASD).

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Hydrogel method form synthetic scaffolds to support formation of blood vessels in engineered tissues

Next-generation hydrogels can form synthetic scaffolds to support the formation of replacement tissues and organs in the emerging area of regenerative medicine. Embedding peptides into the hydrogels stimulates the growth of essential microvascular networks to ensure a good blood supply.

12 Jul 2013

Scientists discover bacterium that stores biodegradable plastic

In Bolivia, in the largest continuous salt desert in the world, researchers from the Polytechnic University of Catalonia have found a bacterium that stores large amounts of PHB, a prized polymer. This biodegradable plastic is used by the food and pharmaceutical industries, for example to produce nanospheres to transport antibiotics.

11 Jul 2013

Biotechnology News and Research

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

HemoShear announces milestone in development of predictive drug safety systems

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Audentes Therapeutics closes $30 million Series A financing

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Chemical compound from ocean microbe offers potential treatments for anthrax

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Zecotek partners with Hamamatsu to commercialize existing imaging technologies

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

Scientists uncover mechanism that controls cell death processes

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

Genome sequencing promises to identify rare mutations that give rise to autism

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Hydrogel method form synthetic scaffolds to support formation of blood vessels in engineered tissues

Scientists discover bacterium that stores biodegradable plastic

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News